RxDoctor Payments Data

Christian Castaneda

Critical Care Medicine · Honolulu, HINPI 1609262435

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by GSK at 52.1% of the total. 2025 is the largest year on record at $29,441, more than ten times the $70 reported in 2019. Among critical care medicine clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,153in general payments, 2019–2025

Across 217 payments — averaging $157.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$18K
  • Intuitive Surgical$8K
  • Olympus Corporation Of The Americas$2K
  • Sanofi$2K
  • Insmed, Inc.$1K
  • Boehringer Ingelheim$762
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$1,5815%
  • Speaking & faculty fees$16,10047%
  • Travel & lodging$4,31413%
  • Food & beverage$6,46019%
  • Education$5,69817%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,153 in reported general payments places this provider in the 95th percentile of 31 critical care medicine providers in Hawaii.

See all critical care medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$42,235
Medicare patients
142
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter156$120,006
NucalaMepolizumab26$101,378
Stiolto RespimatTiotropium Br/Olodaterol Hcl81$40,263
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$7,905
Wixela InhubFluticasone Propion/Salmeterol24$2,313
Albuterol Sulfate HfaAlbuterol Sulfate63$1,583
Omeprazole16$410
Bupropion XlBupropion Hcl11$116
Gabapentin12$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta$17,802$229,289199 claims
Boehringer IngelheimStiolto Respimat$762$40,26381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 critical care medicine providers in Hawaii.

Other critical care medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →